Boston Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$226M Sell
643,175
-81,618
-11% -$29.1M 0.24% 144
2025
Q4
$237M Buy
724,793
+1,059
+0.1% +$336K 0.25% 148
2025
Q3
$204M Sell
723,734
-24,652
-3% -$7.15M 0.21% 158
2025
Q2
$209M Sell
748,386
-55,019
-7% -$15.6M 0.23% 147
2025
Q1
$250M Sell
803,405
-1,458,208
-64% -$431M 0.3% 119
2024
Q4
$590M Sell
2,261,613
-30,567
-1% -$9.07M 0.72% 35
2024
Q3
$738M Sell
2,292,180
-2,230
-0.1% -$729K 0.87% 17
2024
Q2
$718M Buy
2,294,410
+57,076
+3% +$16.8M 0.89% 13
2024
Q1
$635M Buy
2,237,334
+481,214
+27% +$141M 0.76% 28
2023
Q4
$507M Sell
1,756,120
-224,579
-11% -$61.2M 0.67% 36
2023
Q3
$531M Sell
1,980,699
-26,420
-1% -$6.59M 0.74% 33
2023
Q2
$447M Buy
2,007,119
+178,152
+10% +$41.3M 0.6% 54
2023
Q1
$442M Buy
1,828,967
+868,298
+90% +$213M 0.61% 52
2022
Q4
$252M Sell
960,669
-190,671
-17% -$51.1M 0.34% 104
2022
Q3
$260M Sell
1,151,340
-29,919
-3% -$7.25M 0.38% 89
2022
Q2
$287M Buy
1,181,259
+26,858
+2% +$6.58M 0.4% 85
2022
Q1
$279M Buy
1,154,401
+19,366
+2% +$4.45M 0.34% 105
2021
Q4
$255M Buy
1,135,035
+412,337
+57% +$87M 0.31% 115
2021
Q3
$154M Buy
722,698
+29,760
+4% +$6.85M 0.19% 169
2021
Q2
$169M Sell
692,938
-475,983
-41% -$117M 0.22% 158
2021
Q1
$291M Buy
1,168,921
+196,342
+20% +$46.8M 0.39% 85
2020
Q4
$224M Buy
972,579
+952,081
+4,645% +$220M 0.35% 89
2020
Q3
$5.21M Sell
20,498
-1,213
-6% -$301K 0.01% 360
2020
Q2
$5.12M Buy
21,711
+7,640
+54% +$1.74M 0.01% 361
2020
Q1
$2.85M Buy
14,071
+1,764
+14% +$385K 0.01% 394
2019
Q4
$2.97M Buy
12,307
+4,250
+53% +$937K ﹤0.01% 426
2019
Q3
$1.56M Sell
8,057
-2,779
-26% -$533K ﹤0.01% 535
2019
Q2
$2M Buy
10,836
+348
+3% +$62.3K ﹤0.01% 532
2019
Q1
$1.99M Hold
10,488
﹤0.01% 548
2018
Q4
$2.04M Sell
10,488
-49
-0.5% -$9.56K ﹤0.01% 546
2018
Q3
$2.18M Buy
10,537
+362
+4% +$71.3K ﹤0.01% 593
2018
Q2
$1.88M Buy
10,175
+223
+2% +$39.4K ﹤0.01% 669
2018
Q1
$1.7M Buy
9,952
+698
+8% +$128K ﹤0.01% 669
2017
Q4
$1.61M Sell
9,254
-643
-6% -$114K ﹤0.01% 685
2017
Q3
$1.84M Sell
9,897
-1,429
-13% -$253K ﹤0.01% 679
2017
Q2
$1.95M Sell
11,326
-3,860
-25% -$628K ﹤0.01% 660
2017
Q1
$2.49M Buy
15,186
+3,833
+34% +$637K ﹤0.01% 635
2016
Q4
$1.66M Sell
11,353
-728,258
-98% -$110M ﹤0.01% 682
2016
Q3
$123M Sell
739,611
-751,758
-50% -$127M 0.17% 160
2016
Q2
$227M Buy
1,491,369
+35,489
+2% +$5.52M 0.33% 113
2016
Q1
$218M Buy
1,455,880
+18,988
+1% +$2.82M 0.32% 111
2015
Q4
$233M Sell
1,436,892
-9,973
-0.7% -$1.57M 0.33% 99
2015
Q3
$200M Sell
1,446,865
-110,772
-7% -$17.5M 0.31% 109
2015
Q2
$239M Sell
1,557,637
-304,666
-16% -$48.8M 0.34% 91
2015
Q1
$298M Buy
1,862,303
+41,146
+2% +$6.48M 0.44% 67
2014
Q4
$290M Sell
1,821,157
-1,230,655
-40% -$192M 0.44% 68
2014
Q3
$429M Sell
3,051,812
-14,821
-0.5% -$1.94M 0.7% 38
2014
Q2
$363M Sell
3,066,633
-1,904,332
-38% -$220M 0.61% 47
2014
Q1
$613M Sell
4,970,965
-154,702
-3% -$18.8M 1.12% 16
2013
Q4
$585M Buy
5,125,667
+13,425
+0.3% +$1.53M 1.2% 13
2013
Q3
$572M Sell
5,112,242
-93,067
-2% -$10.1M 1.38% 12
2013
Q2
$514M Buy
+5,205,309
New +$540M 1.41% 13

Other funds holding AMGN

Boston Partners's AMGN Position: Q1 2026 in Review

Boston Partners reduced its Amgen (AMGN) stake by 11% in Q1 2026, selling an estimated $29.1M and leaving 643,175 shares worth $226M. The position accounts for 0.24% of the portfolio, ranked #144.

Boston Partners first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $738M in Q3 2024. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Boston Partners held 643,175 shares of Amgen worth $226M as of Q1 2026.
  • Boston Partners sold 81,618 Amgen shares in Q1 2026, an estimated $29.1M.
  • Amgen made up 0.24% of Boston Partners's portfolio in Q1 2026, its #144 holding.
  • Boston Partners first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Boston Partners's Amgen position peaked at $738M in Q3 2024.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.